{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The number of participants who have not experienced disease progression 6 years after therapy initiation","groups":[{"description":"This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.\n\nIbrutinib","id":"OG000","title":"Ibrutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants except for one determined to be ineligible","reportingStatus":"POSTED","timeFrame":"6 years","title":"Progression Free Survival","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}